Results from the pivotal phase III KEYNOTE-859 trial showed that Keytruda (pembrolizumab) plus chemotherapy significantly improved overall survival for patients with human epidermal growth factor receptor 2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, regardless of PD-L1 expression.
In a phase Ib/II clinical trial known as EPCORE NHL-2, a team of researchers—led by Joshua Brody, director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai—showed the benefit of combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma. The results were published earlier this month in the journal Blood.
